Skip to main content

LIVE

OverviewAnalystsInstitutionalElite HoldersEarningsNews
DSGN

Design Therapeutics, Inc.

DSGN

NASDAQ·Healthcare·Biotechnology·Mkt cap $945.6M

$15.14

▲ +0.73%

P/E

-12.83

Mkt Cap

$945.6M

52-Wk Range

$5.28–$17.25

52-Week Range

$5.28 - $17.25

P/E

-12.83

Fwd P/E

-11.41

Beta

1.66

Div Yield

0.00%

Avg Vol

842.6K

Shares Out

61.7M

Mkt Cap

$945.6M

Price action

Price chart

Up 160.1% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Proprietary GeneTAC platform targeting root genetic causes of nucleotide repeat expansion diseases
  • Focused portfolio addressing high-unmet medical needs with limited competitive alternatives
  • Preclinical-stage positioning enabling broad application across multiple rare genetic disorders
  • Experienced management team in genetic medicine and biopharmaceutical development
▼

Bear Case

1 risk

  • Above-average volatility (beta 1.7).

Growth

Stable outlook

Advancement of lead candidates through preclinical development toward IND applications

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Hot

+44.7% over 3m

Quality

Loss-making

Solid business

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 4, 2026

“
Q3 26 RECAP

AUG 3, 2026

Reported EPS of -$0.32 vs -$0.34 consensus (+7.1% surprise).

EPS beat +7.1%

EPS surprise · last 4Q

1 of 1 beats

Estimate

Actual

Q3 26

+7.1%

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

1 analyst · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

1

100%

Hold

0%

Sell

0%

Median Price Target

—

Latest: Oppenheimer · $21.00 · May 4, 2026

View full analyst page →

vs Industry

How DSGN stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.